Physician profile
Aimee Wright
NPI 1942789524
$2,098.05
in general payments reported to CMS, 2019-2025
18 companies · $48.93 in 2025
The $48.93 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $692 · 2023: $253 · 2024: $738 · 2025: $48.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $940.36 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.63 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $180.50 | 2021-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $123.84 | 2021-2024 | Dificid |
| Janssen Biotech, INC. | $108.31 | 2021-2024 | Tremfya, Remicade, Stelara |
| Regeneron Healthcare Solutions, INC. | $85.80 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $77.16 | 2021-2023 | Ocaliva |
| Ethicon US, LLC | $57.88 | 2022 | |
| Pfizer INC. | $56.21 | 2021-2022 | |
| Gilead Sciences, INC. | $53.88 | 2022-2024 | |
| Qol Medical, LLC | $44.49 | 2022-2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $37.48 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $34.20 | 2024 | Iqirvo |
| Celgene Corporation | $33.11 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $20.85 | 2024 | Resmetirom |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.23 | 2024 | |
| Nestle Healthcare Nutrition INC. | $15.99 | 2021 | |
| Daiichi Sankyo INC. | $15.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.